NCT01195649View on ClinicalTrials.gov

Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy

TerminatedOBSERVATIONAL
Enrollment

11

Participants

Timeline

Start Date

December 13, 2010

Primary Completion Date

June 8, 2012

Study Completion Date

August 31, 2012

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Sorafenib (Nexavar, BAY43-9006)

Patients under daily life treatment according to local drug information

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY